Safety of Phentermine for Weight Loss in Patients Taking Rinvoq (Upadacitinib)

Phentermine Overview

• Phentermine is an adrenergic agonist that promotes weight loss by activating the sympathetic nervous system, decreasing food intake and increasing resting energy expenditure 1
• It is FDA-approved only for short-term use (3 months), though many providers prescribe it for longer durations as off-label therapy 2
• The recommended dosage is 15-37.5 mg orally once daily in the morning, with dosage individualized to achieve adequate response with the lowest effective dose 1, 2
• Low-dose phentermine (8 mg) can be prescribed up to 3 times per day 1

Cardiovascular Considerations

• Phentermine can cause mild increases in heart rate and blood pressure, which requires careful monitoring 1, 3
• Patients taking Rinvoq may already have underlying inflammatory conditions that could affect cardiovascular health, making additional cardiovascular effects potentially concerning 3

Potential Drug Interaction Concerns

• Phentermine should not be used with monoamine oxidase inhibitors or other sympathomimetic amines due to potential serious interactions 1
• Patients with active or unstable coronary disease or uncontrolled hypertension are not ideal candidates for phentermine 1

Monitoring Recommendations

• If phentermine is prescribed to a patient on Rinvoq, monitor blood pressure and heart rate periodically 3
• Discontinue phentermine if 5% weight loss is not achieved after 12 weeks on maximum dose 3
• Watch for common side effects including dry mouth, difficulty sleeping, dizziness, and irritability 1
• Start with the lowest effective dose and titrate carefully 1, 2

Alternative Weight Loss Medications

• Orlistat may be a safer alternative for patients with cardiovascular concerns as it works by inhibiting gastrointestinal lipases rather than affecting the sympathetic nervous system 2, 4
• Orlistat blocks absorption of about 30% of ingested fat and is available as prescription (Xenical 120mg) or over-the-counter (Alli 60mg) 2

Clinical Decision-Making Algorithm

• Assess cardiovascular risk factors in the patient taking Rinvoq 2
• If patient has uncontrolled hypertension, active coronary disease, or significant cardiovascular risk factors, avoid phentermine and consider orlistat or other weight loss options 1, 3
• If patient has stable cardiovascular status, consider starting with lowest effective dose of phentermine (15mg or lower) and monitor blood pressure and heart rate at baseline and periodically 1, 2, 3

Phentermine Pre-Treatment Guidelines

Introduction to Phentermine Therapy

• The American Gastroenterological Association recommends screening for cardiovascular disease, measuring baseline blood pressure and heart rate, assessing for contraindications including pregnancy risk, and evaluating renal function before prescribing phentermine 5

Cardiovascular Assessment

• The American Heart Association suggests that phentermine causes mild increases in blood pressure and heart rate through sympathetic nervous system activation, and therefore recommends obtaining baseline measurements 5
• Younger patients without active coronary disease are more appropriate candidates for phentermine therapy 5

Contraindication Screening

• The American College of Gastroenterology recommends that pregnancy status be assessed, as phentermine is contraindicated in pregnancy, and all female patients of reproductive potential require counseling 6, 7
• The American Thyroid Association advises that hyperthyroidism must be excluded before starting phentermine therapy 6, 7
• The American Academy of Ophthalmology states that glaucoma is a contraindication due to sympathomimetic effects 6, 7
• The American Psychiatric Association notes that agitated states or anxiety disorders may be exacerbated by phentermine's stimulant properties 5
• The American College of Clinical Pharmacology recommends that monoamine oxidase inhibitor (MAOI) use is contraindicated during or within 14 days of MAOI administration due to risk of hypertensive crisis 6, 7

Patient Counseling and Documentation

• The National Institute of Diabetes and Digestive and Kidney Diseases advises that patients be counseled that phentermine is FDA-approved only for short-term use (3 months), though off-label longer duration is common in clinical practice 5, 6, 8
• The American Heart Association recommends discussing common side effects, such as dry mouth, difficulty sleeping, dizziness, and irritability, with patients 5
• The Endocrine Society suggests establishing a plan for monitoring response, including discontinuing phentermine if inadequate weight loss is achieved 9

Adipex Treatment Cycle Guidelines

Introduction to Off-Label Use

• The American Gastroenterological Association acknowledges that many experienced clinicians use phentermine for 3-6 months or longer in off-label fashion because obesity is now understood as a chronic metabolic disease requiring long-term management 10, 11, 12

Evidence for Extended Cycles

• Clinical trial data supports 12-week cycles, with some studies extending to 26-28 weeks, demonstrating the effectiveness of extended treatment durations 10, 12

Critical Safety Monitoring

• The American Heart Association recommends that blood pressure and heart rate must be monitored periodically throughout treatment due to phentermine's sympathomimetic effects 12

Documentation for Off-Label Extended Use

• The American Medical Association suggests that if prescribing beyond 12 weeks, document the specific benefits, tolerance profile, adverse effects, and counsel patients regarding off-label use and limited long-term safety data 10, 11

Common Pitfalls to Avoid

• The National Institute of Health warns against confusing phentermine monotherapy with the discontinued "fen-phen" combination (phentermine-fenfluramine), which was associated with valvular heart disease and pulmonary hypertension—these risks were attributed to fenfluramine, not phentermine 10, 11

Prolonged Phentermine Use: Safety Evidence

Introduction to Prolonged Phentermine Use

• The American Gastroenterological Association acknowledges that many practitioners use phentermine longer than 12 weeks in an off-label fashion for weight management, given the chronic nature of the condition 13
• The AGA Clinical Practice Guidelines explicitly state that phentermine can be used for longer than 12 weeks in carefully selected patients without cardiovascular disease, based on recent observational data and guideline acknowledgment 13

Safety and Efficacy

• Pivotal trials for phentermine-topiramate ER showed blood pressure generally declined with treatment, with only modest heart rate increases at higher doses, according to the American College of Gastroenterology 14
• Blood pressure and heart rate must be monitored periodically at every visit throughout treatment when using phentermine beyond 12 weeks, as recommended by the American Heart Association 13
• Female patients of reproductive potential require pregnancy counseling and potentially monthly pregnancy testing, as advised by the American College of Obstetricians and Gynecologists 14

Contraindications and Monitoring

• Phentermine must never be prescribed to patients with any history of cardiovascular disease, uncontrolled hypertension, or other absolute contraindications, as stated by the American College of Cardiology 13
• Patients using phentermine should be monitored for blood pressure and heart rate at every visit, and the medication should be discontinued if the patient has not lost at least 5% of body weight after 12 weeks on maximum dose, according to the National Institutes of Health 13

Phentermine Use Guidelines

Introduction to Phentermine Use

• The American Gastroenterological Association acknowledges that phentermine is used off-label for longer than 12 weeks due to the chronic nature of obesity 15
• The American Diabetes Association notes that phentermine as monotherapy is only approved for short-term use 16

Contraindications and Precautions

• The FDA and medical guidelines contraindicate phentermine in patients with a history of cardiovascular disease, such as coronary artery disease, stroke, arrhythmias, congestive heart failure, or uncontrolled hypertension 15

Monitoring and Safety

• Blood pressure and heart rate must be monitored at every visit throughout treatment when using phentermine beyond 12 weeks, as it causes mild increases in heart rate and blood pressure through sympathetic nervous system activation 15, 16

Cardiovascular Risks and Management of Phentermine

Alternative Weight Management Options

• The American Gastroenterological Association recommends considering alternative weight management medications such as semaglutide 2.4 mg or liraglutide 3.0 mg, which have superior efficacy and different safety profiles, as GLP-1 receptor agonists do not carry the cardiovascular risks associated with sympathomimetic agents 17

Phentermine Administration Guidelines

Introduction to Phentermine Administration

• The American Gastroenterological Association notes that phentermine absorption is not significantly affected by food, unlike orlistat, which must be taken with fat-containing meals 18
• The sympathomimetic effects of phentermine, such as blood pressure and heart rate elevation, occur regardless of food intake and require monitoring at every visit, as recommended by clinical guidelines 18

Practical Considerations for Phentermine Administration

• Clinical evidence suggests that the timing of phentermine administration can impact its efficacy, with some studies indicating that afternoon dosing may better target high-risk eating periods, although the strength of this evidence is limited 18

Phentermine Treatment Guidelines

Introduction to Phentermine Use

• The American Gastroenterological Association and other clinical guidelines suggest that treatment decisions for phentermine should be based on efficacy and ongoing cardiovascular safety monitoring, rather than arbitrary time limits, with no required gap or "washout period" between courses 19, 20
• The FDA approval for phentermine is technically for short-term use, but this reflects historical regulatory constraints rather than safety concerns specific to phentermine monotherapy, and many experienced clinicians use phentermine for 6 months or longer in off-label fashion 19, 20

Decision Making for Phentermine Treatment

• The Mexican clinical practice guidelines explicitly support phentermine use for 6 months or more in most patients, with treatment decisions based on efficacy rather than predetermined cycling schedules 20
• Continue phentermine if ≥5% weight loss is achieved and no cardiovascular contraindications develop, as there is no requirement to stop at 12 weeks, according to the American College of Gastroenterology 19, 20
• Discontinuation criteria include development of cardiovascular disease, uncontrolled hypertension, or other absolute contraindications, as well as inadequate weight loss or intolerable side effects, as recommended by the American Heart Association 20

Safety Monitoring and Contraindications

• Intolerable side effects that don't resolve with dose reduction are a reason for discontinuation, and pregnancy or planning pregnancy is an absolute contraindication for phentermine use, according to the American College of Obstetricians and Gynecologists 20
• No mandatory waiting period is required before restarting phentermine if it was previously discontinued for reasons other than safety concerns, and repeat baseline cardiovascular assessment and screen for new contraindications before restarting, as recommended by the American College of Cardiology 19, 20

Dosing Considerations

• Available formulations of phentermine include 15 mg, 30 mg, and 37.5 mg capsules, and 8 mg and 37.5 mg tablets, with standard dosing once daily in the morning to minimize insomnia risk, according to the American Academy of Sleep Medicine 19
• Low-dose options, such as 8 mg tablets, can be dosed up to 3 times daily and are scored for doses as low as 4 mg, and some clinicians use low doses "as needed" before situations with high risk of hedonic food consumption, though this is expert opinion only 19

Phentermine Prescription Guidelines

Indications and Contraindications

• The American Gastroenterological Association recommends that patients achieve ≥5% weight loss after 12 weeks to continue phentermine treatment, with no cardiovascular contraindications, controlled blood pressure and heart rate, and tolerance to the medication without serious adverse effects 21
• The American College of Gastroenterology suggests that phentermine should be avoided entirely in patients with any history of cardiovascular disease, and safer alternatives such as orlistat or lorcaserin may be considered 22, 21
• Patients with uncontrolled hypertension, untreated hyperthyroidism, current use or within 14 days of monoamine oxidase inhibitors, or pregnancy or inadequate contraception in women of childbearing potential should not be prescribed phentermine 21

Treatment Duration and Monitoring

• The Clinical Gastroenterology and Hepatology guidelines support phentermine use for 6 months or more in most patients, with treatment decisions based on efficacy rather than predetermined cycling schedules, and discontinuation if less than 5% weight loss after 12 weeks on maximum dose 22, 21
• Patients with controlled hypertension may be considered for phentermine treatment with intensive monitoring, as clinical trials showed blood pressure generally declined with treatment 21

Special Considerations

• For patients with type 2 diabetes, the American Diabetes Association recommends considering GLP-1 receptor agonists, which have superior efficacy and cardiovascular safety data, although this is not directly related to phentermine treatment 22
• Female patients of reproductive potential require pregnancy counseling and potentially monthly pregnancy testing when prescribed phentermine beyond 12 weeks 21

Optimal Phentermine Use for Weight Loss

Efficacy and Safety

• The pooled mean weight loss from meta-analysis is approximately 3.6 kg 23
• Orlistat has a pooled mean weight loss of 2.59 kg at 6 months and 2.89 kg at 12 months 23
• Expected outcomes with phentermine include a mean weight loss of approximately 5.1% at 28 weeks, with 46% of patients achieving ≥5% weight loss and 20.8% achieving ≥10% weight loss with 15 mg daily 23

Phentermine Monitoring and Laboratory Guidance

Baseline Cardiovascular Assessment

• Obtain baseline blood pressure and heart rate measurements in all adult patients before initiating phentermine therapy, because the drug can cause mild sympathetic‑mediated increases in these parameters. 24

Ongoing Cardiovascular Monitoring

• Measure blood pressure and heart rate at every clinical visit throughout phentermine treatment, with particular emphasis when therapy extends beyond the FDA‑approved 12‑week duration. 24

Laboratory Testing Recommendations

• Routine metabolic panels, lipid profiles, liver function tests, or other laboratory studies are not mandated by current phentermine monitoring guidelines; focus should remain on cardiovascular parameters and weight‑loss efficacy. 24

Historical Context and Safety Misconceptions

• Phentermine monotherapy should not be confused with the discontinued “fen‑phen” combination; valvular heart disease and pulmonary hypertension were linked to fenfluramine, not to phentermine itself. 24

Off‑Label Duration and Treatment Decisions

• Although the FDA approves phentermine for a maximum of 12 weeks, many clinicians prescribe it off‑label for up to 6 months or longer, basing continuation on demonstrated efficacy and cardiovascular safety rather than an arbitrary time limit. 24
• A mandatory washout period is not required between treatment courses if the prior discontinuation was for non‑safety reasons. 24

Blood Pressure Effects During Therapy

• Observational data indicate that systolic and diastolic blood pressure often decrease during phentermine therapy, likely secondary to weight loss. 24
• One study reported average reductions of approximately ‑7.3 mmHg systolic and ‑5.4 mmHg diastolic blood pressure after 52 weeks of treatment. 24

Safety and Efficacy of Tirzepatide Monotherapy vs. Combination with Phentermine

Guideline Recommendations

• The American Gastroenterological Association (AGA) guideline states that combining phentermine with other weight‑loss medications, including tirzepatide, is not supported outside of FDA‑approved fixed‑dose combinations. 25

Efficacy of Tirzepatide

• Tirzepatide monotherapy produces a mean weight loss of ≈21 % at 72 weeks (15 mg dose), with ≈40 % of patients achieving ≥25 % total body‑weight loss. 26
• The AGA guideline and supporting clinical data recommend tirzepatide as first‑line pharmacotherapy for obesity because of its superior efficacy. 26
• In addition to weight loss, tirzepatide provides metabolic benefits, including improvements in lipids, blood pressure, and glucose control. 27

Safety Profile of Phentermine

• Phentermine is associated with modest weight loss (≈6 % at 6 months) and produces mild increases in heart rate and blood pressure through sympathetic nervous‑system activation. 28
• Prior to prescribing phentermine, patients should be screened for cardiovascular contraindications such as active coronary disease, uncontrolled hypertension, or significant cardiovascular risk factors. 28

Clinical Algorithm for Weight‑Loss Pharmacotherapy

• Second‑line option: If tirzepatide is unavailable, unaffordable, or contraindicated, phentermine monotherapy may be considered, with the requirement to discontinue if <5 % weight loss after 12 weeks at the maximum dose. 28
• Approved combination products: When combination therapy is desired, only FDA‑approved fixed‑dose combinations (e.g., phentermine/topiramate ER) should be used; this regimen yields ≈9.8 % weight loss versus ≈1 % with placebo and has established safety data. 27

Regulatory and Documentation Considerations for Off‑Label Use

• If a clinician elects to use phentermine + tirzepatide off‑label, documentation must include a specific rationale, obtain informed consent that explains the lack of safety data, and may involve consultation with an obesity‑medicine specialist. 25

Phentermine Use in Patients with Controlled Hypertension

Eligibility Criteria

Monitoring Protocol

Expected Blood‑Pressure Effects

Regulatory Status and Off‑Label Practice

Safety Misconceptions

Extended Use of Phentermine: Evidence‑Based Guideline Summary

Off‑Label Duration

• The American Gastroenterological Association states that many experienced clinicians prescribe phentermine for 3–6 months or longer off‑label because obesity is now viewed as a chronic metabolic disease requiring long‑term management (expert opinion). 31

Cardiovascular Monitoring

• When phentermine is used beyond 12 weeks, systolic and diastolic blood pressure and heart rate must be measured at every clinical encounter (routine safety monitoring). 31
• Phentermine exerts mild sympathomimetic activity that can raise heart rate and blood pressure (pharmacologic effect). 31
• Observational cohorts report that, despite its sympathomimetic action, average blood pressure tends to fall during therapy (≈ ‑7 mm Hg systolic, ‑5 mm Hg diastolic at 52 weeks), likely secondary to weight loss (low‑quality evidence). 31
• Pivotal randomized trials of the phentermine‑topiramate extended‑release formulation demonstrated overall declines in blood pressure with only modest increases in heart rate at higher doses (high‑quality RCT data). 31

Absolute Contraindications

• Phentermine must not be prescribed to any patient with a history of cardiovascular disease—including coronary artery disease, stroke, arrhythmias, congestive heart failure, or uncontrolled hypertension (strong guideline recommendation). 31
• Additional absolute contraindications supported by the same source:
  
  • Current use of, or use within 14 days of, monoamine‑oxidase inhibitors (risk of hypertensive crisis).
  • Untreated hyperthyroidism (risk of arrhythmias and seizures).
  • Pregnancy or inadequate contraception in women of child‑bearing potential. (expert consensus). 31

Use in Patients with Controlled Hypertension

• Phentermine may be initiated in individuals whose hypertension is well‑controlled (systolic < 140 mm Hg, diastolic < 90 mm Hg) on antihypertensive regimens that do not contain MAO inhibitors (moderate‑strength recommendation). 31
• Clinical trials that enrolled participants with controlled hypertension (baseline < 160/100 mm Hg) found that blood pressure generally decreased during phentermine therapy (moderate‑quality trial data). 31

Dosing Considerations

• Standard dosing is 15–37.5 mg taken once daily in the morning to minimize insomnia (expert opinion).
• Low‑dose formulations (8 mg tablets) can be administered up to three times daily, with scored tablets allowing doses as low as 4 mg (pharmacologic flexibility). 31
• Some clinicians employ low‑dose phentermine “as needed” before situations with high risk of hedonic food intake (expert opinion). 31

Safety Evidence and Remaining Gaps

• No large cardiovascular outcome trials have evaluated long‑term (> 12 weeks) phentermine monotherapy (evidence gap). 31
• Consequently, clinicians should exercise caution with prolonged use, especially in patients who possess cardiovascular risk factors (cautious recommendation). 31

Historical Misconception – Fen‑Phen

• The valvular heart disease and pulmonary hypertension observed with the discontinued fen‑phen combination were attributable to fenfluramine, not to phentermine itself (clarifying evidence). 31

Phentermine Use: Contraindications, Evaluation, and Management Guidelines

Absolute Contraindications

• Phentermine should never be prescribed to patients with any history of cardiovascular disease (including coronary artery disease, stroke, arrhythmias, congestive heart failure, or uncontrolled hypertension) because of the risk of serious adverse events. 32
• Phentermine is contraindicated throughout pregnancy and in women of child‑bearing potential without reliable contraception, as it is classified as FDA pregnancy category X. 32
• Current use of monoamine‑oxidase inhibitors (MAOIs) or use within 14 days of discontinuation contraindicates phentermine due to the risk of hypertensive crisis. 32
• Untreated hyperthyroidism is a contraindication because additive sympathomimetic effects may precipitate arrhythmias. 32
• Angle‑closure glaucoma is a contraindication; sympathomimetic agents can worsen intra‑ocular pressure. 32
• Patients with agitated states or a history of drug abuse should not receive phentermine, given its Schedule IV amphetamine‑like properties. 32
• Concomitant use of other sympathomimetic amines is contraindicated because of additive cardiovascular stimulation. 32

Pre‑Treatment Evaluation

• Verify that the patient’s body‑mass index (BMI) is ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight‑related comorbidity, before initiating phentermine. 32
• Perform pregnancy screening and confirm a negative result in all women of reproductive potential prior to prescribing. 32
• Conduct a medication review to identify recent MAOI exposure (within 14 days), other sympathomimetics, and alcohol use. 32
• Obtain a detailed medical history to exclude hyperthyroidism, glaucoma, cardiovascular disease, psychiatric disorders (e.g., anxiety, agitation), and substance‑use disorders. 32

Dosing and Administration

• The standard adult dose is 15–37.5 mg taken orally once daily in the morning to reduce the risk of insomnia. 32

Treatment Continuation & Monitoring

• Continue phentermine only if the patient achieves ≥ 5 % weight loss after 12 weeks of therapy. 32
• Discontinue phentermine if the patient achieves < 5 % weight loss after 12 weeks on the maximum tolerated dose. 32
• Monitor blood pressure and heart rate at every clinical visit throughout treatment. 32
• Assess body weight monthly for the first three months, then at least every three months thereafter. 32

Adverse‑Effect Profile

• Central‑nervous‑system effects may include overstimulation, restlessness, dizziness, insomnia, irritability, and headache. 32
• Gastro‑intestinal effects may include dry mouth, unpleasant taste, constipation, and diarrhea. 32
• Cardiovascular effects may include palpitations, tachycardia, and modest elevation of blood pressure. 32

Safer Alternatives for High‑Risk Patients

• For patients with cardiovascular disease or significant cardiovascular risk, recommend non‑sympathomimetic agents such as orlistat or lorcaserin. 32
• GLP‑1 receptor agonists (e.g., semaglutide 2.4 mg, liraglutide 3.0 mg) provide superior weight‑loss efficacy (≈21 % with tirzepatide at 72 weeks vs. ≈5.1 % with phentermine at 28 weeks) and have favorable cardiovascular safety profiles. 32
• Orlistat is appropriate for patients with cardiovascular contraindications, although its efficacy is lower (≈3.1 % weight loss at 1 year). 32

Clinical Decision Rules

• Do not continue phentermine beyond 12 weeks if the patient has achieved < 5 % weight loss; consider alternative therapy. 32
• Do not overlook pregnancy screening in women of reproductive age, as a positive pregnancy test is an absolute contraindication to phentermine. 32

Phentermine Use in Adult Obesity – Evidence‑Based Guidelines

Indications and Duration

• The American Gastroenterological Association (AGA) notes that, although FDA approval limits phentermine to 12 weeks, clinicians commonly prescribe it for 3–6 months or longer because obesity is a chronic metabolic disease that often requires long‑term pharmacologic management. 33

Continuation and Discontinuation Criteria

• Phentermine may be continued beyond the initial 12‑week period when the patient has achieved ≥ 5 % weight loss after 12 weeks of therapy. 33
• Phentermine should be discontinued if the patient shows < 5 % weight loss after 12 weeks on the maximum tolerated dose, as early response predicts long‑term success. 33

Pre‑Treatment Evaluation

• Prior to initiating phentermine, clinicians should confirm a BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with at least one weight‑related comorbidity) and obtain a comprehensive medical history to exclude hyperthyroidism, glaucoma, cardiovascular disease, psychiatric disorders, and substance‑use disorders. 33

Cardiovascular Monitoring

• Blood pressure and heart rate must be measured at every clinical visit throughout phentermine therapy to detect any sympathomimetic effects. 33

Lifestyle Integration

• Phentermine therapy should be combined with an ≈ 500 kcal daily caloric deficit relative to estimated energy needs. 33
• Patients should engage in ≥ 150 minutes per week of moderate‑intensity aerobic activity while on phentermine. 33

Follow‑Up Monitoring Schedule

• Schedule monthly visits for the first 3 months to assess weight change, vital signs, efficacy, and tolerability.
• After the initial period, conduct follow‑up visits every 3 months to re‑evaluate weight, blood pressure, cardiovascular risk factors, and medication adherence.
• Discontinue therapy if the patient fails to achieve ≥ 5 % weight loss after 12 weeks on the maximum tolerated dose (as noted above). 33

Combination Therapy

• The only FDA‑approved fixed‑dose combination is phentermine/topiramate ER (15 mg/92 mg), which produces an average ≈ 9.8 % weight loss at 56 weeks. 33

Phentermine Therapy Guidelines for Adult Obesity

Indications & Initial Dosing

• Adults with a body‑mass index ≥ 30 kg/m² (or ≥ 27 kg/m² with at least one obesity‑related comorbidity such as hypertension, dyslipidemia, diabetes, pre‑diabetes, or abdominal obesity) should be started on phentermine 15–37.5 mg taken orally once daily in the morning; dose selection aims to minimize insomnia risk. 34

Treatment Duration & Continuation Criteria

• Phentermine is FDA‑approved for short‑term use up to 12 weeks; clinicians may extend therapy to 3–6 months or longer when obesity is treated as a chronic condition, provided efficacy criteria are met. 34
• Continue therapy beyond 12 weeks only if the patient has achieved a ≥5 % reduction in body weight after the initial 12‑week period on the maximum tolerated dose. 34
• Discontinue phentermine if the patient fails to achieve ≥5 % weight loss after 12 weeks despite optimal dosing. 34

Contraindications & Safety Precautions

• Absolute contraindications include any history of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension), current or recent use of monoamine‑oxidase inhibitors, pregnancy or inadequate contraception, untreated hyperthyroidism, angle‑closure glaucoma, active psychiatric agitation or substance‑use disorder, and concurrent use of other sympathomimetic agents. 34

Baseline Evaluation Before Initiation

• Obtain baseline blood pressure and heart rate and verify the absence of the above cardiovascular and other contraindications before prescribing phentermine. 34

Monitoring Protocol During Therapy

• Measure blood pressure and heart rate at every clinical visit throughout the course of treatment. 34

Use in Patients with Controlled Hypertension

• Phentermine may be prescribed to individuals whose hypertension is well‑controlled (systolic < 140 mmHg and diastolic < 90 mmHg) on antihypertensive regimens that do not include MAO inhibitors; ongoing cardiovascular monitoring remains mandatory. 34

Expected Weight‑Loss Outcomes

• Average weight loss with phentermine is approximately 3.6–4.7 kg (3.6–5.1 % of total body weight) after 12–28 weeks of therapy. 34
• At a dose of 15 mg daily, about 46 % of patients achieve ≥5 % weight loss and 20.8 % achieve ≥10 % weight loss by week 28. 34

Lifestyle Integration Requirements

• Pharmacologic therapy must be combined with a daily caloric deficit of roughly 500 kcal (total intake 1,200–1,800 kcal/day). 34
• Patients should also engage in ≥150 minutes per week of moderate‑intensity aerobic activity (e.g., walking 30 minutes most days). 34

Clarification of Safety Misconception

• Phentermine monotherapy is distinct from the discontinued “fen‑phen” combination; the valvular heart disease and pulmonary hypertension associated with fen‑phen were caused by fenfluramine, not by phentermine. 34

Alternative Pharmacologic Options for High‑Risk Patients

• For individuals in whom phentermine is contraindicated due to cardiovascular risk, or‑listat 120 mg taken three times daily with meals can be used, producing an average weight loss of about 2.9 kg after 12 months. 34

Phentermine: Safety, Indications, and Monitoring Guidelines

Indications and Duration

• Phentermine is FDA‑approved as a short‑term adjunct (up to 12 weeks) for adults with a body‑mass index ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight‑related comorbidity such as controlled hypertension, diabetes, or hyperlipidaemia. 35
• Many clinicians prescribe phentermine off‑label for 3–6 months or longer because obesity is now recognised as a chronic metabolic disease requiring long‑term management. 35

Contraindications

• Absolute contraindication: any history of cardiovascular disease—including coronary artery disease, stroke, arrhythmias, congestive heart failure, or uncontrolled hypertension. 35

Pre‑Treatment Evaluation

• Baseline blood‑pressure and heart‑rate measurements must be obtained before initiating phentermine therapy. 35

Monitoring and Discontinuation Criteria

• Blood pressure and heart rate should be measured at every clinical visit throughout treatment. 35
• Therapy should be discontinued if the patient achieves < 5 % weight loss after 12 weeks on the maximum tolerated dose. 35

Cardiovascular Safety Evidence

• Phentermine monotherapy has not been associated with an increased risk of major adverse cardiac events compared with usual care, according to a recent review. 35
• The valvular heart disease and pulmonary hypertension reported with the discontinued “fen‑phen” combination were caused by fenfluramine, not by phentermine. 35

Off‑Label Extended Use

• The American Gastroenterological Association acknowledges that clinicians often use phentermine beyond the FDA‑approved 12‑week period for chronic weight‑management. Continuation beyond 12 weeks is appropriate only when:
  
  • ≥ 5 % weight loss has been achieved after the initial 12 weeks,
  • No new cardiovascular contraindications have emerged,
  • Blood pressure and heart rate remain controlled, and
  • The patient tolerates the medication without serious adverse effects. 35

Alternative Therapies for High‑Risk Patients

• For patients with cardiovascular disease or high cardiovascular risk, orlistat (120 mg three times daily with meals) is an alternative; it provides modest weight loss (≈ 2.9 kg at 12 months) and has no cardiovascular contraindications. 35

Abuse Potential and Controlled Substance Status

• Phentermine is classified as a Schedule IV controlled substance but carries a low risk of dependency or abuse, with no data supporting addictive potential. 35

Prescribing Pitfalls

• Phentermine must not be combined with other weight‑loss medications outside FDA‑approved fixed‑dose combinations (e.g., phentermine/topiramate ER), because safety and efficacy of such combinations have not been established. 35

Telehealth Prescribing Considerations

• Virtual visits for phentermine prescribing are non‑inferior to in‑person visits for achieving meaningful weight loss; the same pre‑treatment screening, ongoing monitoring, and continuation criteria apply in telehealth settings. 35